FDA Seeks Input On GI Drug Bioequivalence Standards From Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will also offer a revised bio-inequivalence proposal at an Oct. 20 Pharmaceutical Science Advisory Committee meeting. On Oct. 19, the committee will discuss FDA's Critical Path initiative, risk-based GMP progress and parametric interval testing.